Table 3.
Study | Patient population | Therapy | Duration (wk) | SVR | Comments |
SAPPHIRE-I | First-line therapy | OBV + PTV/r + DSV + R | 12 | 96% | No cirrhosis |
SAPPHIRE-II | Re-therapy | OBV + PTV/r + DSV + R | 12 | 96% | No cirrhosis |
TURQUOISE-II | Cirrhosis | OBV + PTV/r + DSV + R | 12 | 92% | GT1a 89% |
GT1b 99% | |||||
OBV + PTV/r + DSV + R | 24 | 96% | GT1a 95% | ||
GT1b 100% | |||||
PEARL-II | Re-therapy, GT1b | OBV + PTV/r + DSV | 12 | 100% | No cirrhosis |
OBV + PTV/r + DSV + R | 12 | 97% | No cirrhosis | ||
PEARL-III | First-line therapy, GT1b | OBV + PTV/r + DSV | 12 | 99% | No cirrhosis |
OBV + PTV/r + DSV + R | 12 | 99% | No cirrhosis | ||
PEARL-IV | First-line therapy, GT1a | OBV + PTV/r + DSV | 12 | 90% | No cirrhosis |
OBV + PTV/r + DSV + R | 12 | 97% | No cirrhosis |
OBV: Ombitasvir; PTV: Paritaprevir; DSV: Dasabuvir; R: Ribavirin; r: Ritonavir; SVR: Sustained virological response.